基层医疗环境中肝脏硬度检测发现丙型肝炎患者晚期纤维化高患病率并预测肝脏相关事件
该前瞻性队列研究从澳大利亚维多利亚州21家基层诊所纳入780例社区管理的慢性丙型肝炎患者,中位肝脏硬度值为6.9 kPa,16.5%存在晚期纤维化风险(LSM≥12.5 kPa),与医院队列相比肝硬化风险比例无差异(p=0.169);中位随访15.2个月,LSM≥12.5 kPa者肝脏相关事件发生率为9.3%,LSM 24 kPa对肝脏相关事件预测力最高(风险比152;p<0.001)。
要点
- 社区管理的慢性丙型肝炎患者中16.5%存在晚期纤维化风险(LSM≥12.5 kPa)。
- 社区与医院队列的肝硬化风险比例无差异(p=0.169)。
- LSM 24 kPa对肝脏相关事件预测力最高(风险比152;p<0.001)。
核心结论
- 基层医疗管理的慢性丙型肝炎中,基于LSM判定的晚期纤维化患病率显著且与医院队列相当。
- 本研究支持将LSM作为慢性丙型肝炎人群的社区筛查工具,并提示其可能具有预测肝脏相关事件的作用。
研究设计与样本
- 前瞻性队列研究,从澳大利亚维多利亚州21家基层诊所招募成年慢性丙型肝炎患者,纳入标准为丙型肝炎持续>6个月、近期(<18个月)无专科干预且无肝细胞癌病史。
- 临床评估、LSM和采血在基层医疗完成,并招募医院队列用于比较,参与者纵向随访监测肝脏相关事件。
- 26个月内共招募780例社区患者纳入分析。
主要发现
- 社区患者中位LSM为6.9 kPa,16.5%存在晚期纤维化风险(LSM≥12.5 kPa),其中8.5%无晚期肝病实验室特征。
- 社区与医院队列的肝硬化风险比例无差异(p=0.169)。
- 危险饮酒、年龄增长、体重指数升高和丙氨酸氨基转移酶升高是LSM升高的独立预测因素。
- 中位随访15.2个月,LSM≥12.5 kPa者中9.3%发生肝脏相关事件。
- LSM 24 kPa对肝脏相关事件的预测力最高(风险比152;p<0.001)。
关键数值与推荐
- 晚期纤维化风险定义为LSM≥12.5 kPa,社区患者中该比例为16.5%。
- 肝硬化风险比例在社区与医院队列间无差异(p=0.169)。
- LSM 24 kPa对肝脏相关事件的预测力最高(风险比152;p<0.001)。
临床怎么用
- 作者认为LSM可作为慢性丙型肝炎人群在丙型肝炎治疗前的社区筛查工具。
- 作者指出LSM在预测肝脏相关事件方面可能具有作用。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND & AIMS: As many as 70% of individuals with chronic hepatitis C (CHC) are managed solely in primary care. The aims of this study were to determine the prevalence of elevated liver stiffness measurement (LSM) in a cohort of community managed patients with CHC and to evaluate predictors of advanced liver disease and liver-related events. METHODS: A prospective cohort of adult patients with CHC were recruited from 21 primary care practices throughout Victoria, Australia. Inclusion criteria included the presence of CHC for >6 months, no recent (<18 months) specialist input and no history of hepatocellular carcinoma. Clinical assessment, LSM and phlebotomy were carried out in primary care. A hospital cohort was recruited for comparison. Participants were followed longitudinally and monitored for liver-related events. RESULTS: Over 26 months, 780 community patients were recruited and included in the analysis. The median LSM was 6.9 kPa in the community, with 16.5% of patients at risk of advanced fibrosis (LSM ≥12.5 kPa); of these 8.5% had no laboratory features of advanced liver disease. The proportion at risk of cirrhosis was no different between the community and hospital cohorts (p = 0.169). At-risk alcohol consumption, advancing age, elevated body mass index and alanine aminotransferase were independent predictors of elevated LSM. Over a median follow-up of 15.2 months, liver-related events occurred in 9.3% of those with an LSM ≥12.5 kPa. An LSM of 24 kPa had the highest predictive power for liver-related events (hazard ratio152; p <0.001). CONCLUSION: The prevalence of advanced fibrosis, as determined by LSM, in primary care managed CHC is significant and comparable to a hospital cohort. Furthermore, this study supports the use of LSM as a community screening tool in a CHC population and indicates a possible role in predicting liver-related events. LAY SUMMARY: The prevalence of advanced liver disease in primary care managed hepatitis C is unknown. Our data suggests that rates of advanced fibrosis in the community are significant (16.5%), often underdiagnosed and comparable to rates seen in specialist referral centres. Liver stiffness measurement is a feasible community screening tool prior to hepatitis C therapy and can predict liver-related adverse events.
引用
- Bloom S, Kemp W, Nicoll A, et al. Liver stiffness measurement in the primary care setting detects high rates of advanced fibrosis and predicts liver-related events in hepatitis C. J Hepatol. 2018. PMID: 29709676. doi:10.1016/j.jhep.2018.04.013
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。